Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?

Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call Transcript

12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September

Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.

Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know

Altimmune (ALT) stock sold off after the company announced its plan to scrap its COVID19 vaccine programs, and ALT is currently trading at an enterprise value of around US$120M. We believe ALT's NASH and obesity pipeline drives most of its value. The recent sell-off offers an attractive low-risk entry point for long-term investors.

Altimmune: NASH And Obesity At The End Of The COVID Tunnel

Alphabet

Johnson & Johnson

Walgreens

Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.

Wall Street Heads Into H2 With Stocks on a Streak

The company halts development on both a COVID-19 vaccine and a drug targeting the disease.

Why Altimmune Is Crashing Today

The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 35% during intraday trading. This is why it happened.

ALT Stock Price Falls Over 35%: Why It Happened

Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the development of its nasal Covid-19 vaccine after an early stage trial exhibited immune responses that missed expectations.

ALT in Freefall After Covid-19 Vaccine Trials Scrapped

Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 1/2 trial for T-COVID, single-dose intranasal therapeutic for early COVID-19, completed dosing in two of the three planned dose cohorts but could not fill the third cohort with patients over the age of 65 or with increased risk due to pre-existing comorbidities.

Altimmune Stock Tanks On Double Bad News From COVID-19 Program

Altimmune Inc. ALT shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated. Altimmune shares fell 33% after hours, following a 2.5% decline to close at $15.90.

Altimmune stock falls after it drops development of nasal COVID-19 vaccine

GAITHERSBURG, Md., June 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.

Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial

The stock price of Altimmune, Inc. (Nasdaq: ALT) increased by 16.49% yesterday. This is why it happened.

ALT Stock Price Increased 16.49%: Why It Happened

Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was achieved at six weeks with a weekly dose of 1.8mg.

Altimmune's Stock Trades In A Double Bottom Pattern: What's Next?

An experimental new weight loss drug produced compelling data in an early stage clinical trial.

Here's Why Altimmune Stock Is Surging Today

Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers. The study is currently being conducted in Australia.

Altimmune's ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%

GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application.

Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers

Alternus Energy PLC (NOTC:ALT) told investors it had acquired, for cash and shares, a 60% stake in Netherlands-based clean energy group Unisun Energy Holding B.V, making the former a "fully vertically integrated independent solar power producer" with activities across the solar power chain. The deal also provides a strong platform for Alternus to grow in the Netherlands, adding over 250 MW of solar projects at various stages of development.

Alternus Energy buys 60% stake in Netherlands-based clean energy group Unisun Energy Holding B.V

Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine neutralized the COVID-19 B.1.351 variant that originated in South Africa.

Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows

Do Options Traders Know Something About Altimmune (ALT) Stock We Don't?

Altimmune is slated to report Phase I clinical data from their intranasal COVID-19 vaccine, AdCOVID, in June of this year. New preclinical data reveals that AdCOVID has the potential of sterilizing immunity and preventing transmission. I believe this is the key to putting an end to the pandemic.

Altimmune: Managing A Position Around A Critical AdCOVID Readout

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing intranasal vaccines, immune-modulating therapies, and treatments for liver disease. Altimmune's pipeline consists of intranasal vaccines for COVID-19, anthrax, and influenza; an intranasal immune modulating therapeutic for COVID-19; and next-generation peptide therapeutics for non-alcoholic steatohepatitis and chronic hepatitis b.

Altimmune: Q2 2021 Holds Large Upside Potential With 3 Trial Data Readouts And BARDA Decision

Altimmune, Inc.'s (ALT) CEO Vipin Garg on Q1 2021 Results - Earnings Call Transcript

News for Altimmune Stock (ALT)